Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 5/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 9/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145676 | 1.00 | TNF (0.50) | TNFALOX5APFEN1MAP3K12WDR5 | |
| SCHEMBL29794987 | 1.00 | TNF (0.50) | TNFALOX5APFEN1MAP3K12WDR5 | |
| SCHEMBL29794966 | 1.00 | TNF (0.50) | TNFALOX5APFEN1MAP3K12WDR5 | |
| SCHEMBL18145763 | 1.00 | TNF (0.50) | TNFALOX5APFEN1MAP3K12WDR5 | |
| SCHEMBL18145753 | 1.00 | TNF (0.50) | TNFALOX5APFEN1MAP3K12WDR5 | |
| SCHEMBL18157271 | 1.00 | TNF (0.50) | TNFALOX5APFEN1MAP3K12WDR5 | |
| SCHEMBL29794937 | 1.00 | TNF (0.50) | TNFALOX5APFEN1MAP3K12WDR5 | |
| SCHEMBL19818295 | 0.94 | TNF (0.45) | TNFALOX5APFEN1WDR5PIK3CA | |
| SCHEMBL19818293 | 0.94 | TNF (0.45) | TNFALOX5APFEN1WDR5PIK3CA | |
| SCHEMBL19818294 | 0.94 | TNF (0.45) | TNFALOX5APFEN1WDR5PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | claimed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023178199-A2 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| US-10273238-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-08-02 | — | — | US | disclosed |
| US-9879016-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | TNF 1/4885ALOX5AP 1677/4885FEN1 4483/4885 |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | TNF 5/4885ALOX5AP 3315/4885FEN1 1011/4885 |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | TNF 1/4885ALOX5AP 1677/4885FEN1 4483/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | TNF 4166/4885ALOX5AP 2009/4885FEN1 3406/4885 |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, SSB | TNF 5/4885ALOX5AP 3342/4885FEN1 1117/4885 |
| US-10273238-B2 | Indazolones as modulators of TNF signaling | TNF, TNFRSF9, TNFRSF1A | TNF 1/4885ALOX5AP 1677/4885FEN1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.